Virtual Challenging Case Clinic:
B-Cell Lymphomas
- Delve into treatment paradigms, available therapies, and agents under development for various subtypes of B-cell lymphomas
- Expert insights on particularly challenging patient cases submitted by actual attendees


Course Director
John P. Leonard, MD
Senior Associate Dean for
Innovation and Initiatives
Executive Vice Chair,
Weill Department of Medicine
Richard T. Silver Distinguished Professor of Hematology & Medical Oncology
Weill Cornell Medical College
New York, New York
Agenda
- Welcome, Introductions, and
Pre-session Survey - General Disease State and
Treatment Guidelines - Expert Insights: Faculty-submitted cases
- Case Presentation, Polling Questions,
and Discussion - Q&A
- Conclusion and Post-session Survey
Upcoming Webinars
MAY 18, 2022
University of Michigan Health | Ann Arbor, Michigan
JUNE 8, 2022
JULY 13, 2022
Memorial Sloan Kettering Cancer Center | New York ,New York
AUGUST 10, 2022
Dana-Farber Cancer Institute | Boston, Massachusetts
SEPTEMBER 14, 2022
University of Miami Sylvester Comprehensive Cancer Center | Miami, Florida
NOVEMBER 9, 2022
Dana-Farber Cancer Institute | Boston, Massachusetts
DECEMBER 14, 2022
University of Nebraska Medical Center | Omaha, Nebraska
FEBRUARY 8, 2023
Weill Cornell Medicine | New York, New York
Weill Cornell Medicine | New York, New York
Broadcast April 12, 2023
The University of Texas MD Anderson Cancer Center | Houston, Texas
Peter Martin, MD
Weill Cornell Medicine l New York, New York
Sonali Smith, MD, FASCO
The University of Chicago | Chicago, Illinois
Broadcast January 11, 2023
Diffuse Large B-cell Lymphoma
University of Nebraska Medical Center l Omaha, Nebraska
University of Rochester Medical Center | Rochester, New York
Brad Kahl, MD
Washington University School of Medicine | St. Louis, Missouri
Broadcast October 12, 2022
CNS Lymphoma
Recordings From Previous Webinars: 2021 Series
Recordings From Previous Webinars: 2021 Series
Virtual Challenging Case Clinic: B-cell Lymphomas: Updates from ASH 2021
Virtual Challenging Case Clinic: B-cell Lymphomas: MZL
Virtual Challenging Case Clinic: B-cell Lymphomas: CLL
Matthew Davids, MD, MMSc
Dana-Farber Cancer Institute | Boston, MA
John P. Leonard, MD
Weill Cornell Medicine | New York, New York
Broadcast October 13, 2021
James Rubenstein, MD
University of California San Francisco | San Francisco, CA
John P. Leonard, MD
Weill Cornell Medicine | New York, New York
Broadcast September 15, 2021
Virtual Challenging Case Clinic: B-cell Lymphomas:
Updates from ASCO, EHA, and ICML
John P. Leonard, MD
Weill Cornell Medicine | New York, New York
Gilles Salles, MD, PhD
Memorial Sloan Kettering | New York
Broadcast August 11, 2021
US National Clinical Trial Update Roundtable
John P. Leonard, MD
Weill Cornell Medicine | New York, New York
Brad Kahl, MD
Washington University School of Medicine | Saint Louis, Missouri
Jonathan Friedberg MD, MMSc
University of Rochester Medical Center | Rochester, New York
Broadcast July 14,2021
Hodgkin’s Lymphoma
Ann LaCasce, MD
Dana-Farber Cancer Institute | Boston, Massachusetts
Broadcast June 9, 2021
Mehdi Hamadani, MD
Medical College of Wisconsin | Milwaukee, Wisconsin
Broadcast May 12, 2021
Mantle Cell Lymphoma
Jonathon Cohen, MD, MS
Winship Cancer Center of Emory University | Atlanta, Georgia
Broadcast on April 14, 2021
Recordings From Previous Webinars: 2020 Series
John P. Leonard, MD
Weill Cornell Medicine | New York, New York
Broadcast on January 13, 2021
Jonathon Cohen, MD, MS
Winship Cancer Institute of Emory University | Atlanta, Georgia
Broadcast on December 9, 2020
Peter Martin, MD
Weill Cornell Medicine | New York, New York
Broadcast on November 11, 2020
Kerry Savage, MD
University of British Columbia | Vancouver, Canada
Broadcast on October 14, 2020
Jonathan Friedberg, MD, MMSc
University of Rochester Medical Center | Rochester, New Yorkj
Broadcast on September 9, 2020
John P. Leonard, MD
Weill Cornell Medical College | New York, New York
Broadcast on August 12, 2020
Matthew Davids, MD, MMSc
Dana-Farber Cancer Institute | Boston, Massachusetts
Broadcast on July 8, 2020
Andrew Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center | New York, New York
Broadcast on June 10, 2020
Mitchell Smith, MD, PhD
George Washington University | Washington, District of Columbia
Broadcast on May 13, 2020
Julie Vose, MD, MBA
University of Nebraska Medical Center | Omaha, Nebraska
Broadcast on April 8, 2020
This activity is supported by independent educational grants from AstraZeneca, Bristol-Myers Squibb, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc.
The target audience for this activity is clinicians who treat patients with indolent and aggressive B-cell lymphomas: hematologists, medical oncologists, oncology nurses, nurse practitioners, oncology pharmacists, and other healthcare professionals.
After completing this activity, participants should be better able to:
- Assess best available evidence regarding treatment of indolent and aggressive B-cell lymphomas
- Evaluate the clinical implications of emerging data regarding B-cell lymphoma treatment approaches
- Plan strategies to address complicated B-cell lymphoma cases
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC or Bio Ascend.
This activity is supported by independent educational grants from AstraZeneca, Bristol-Myers Squibb, and Epizyme, Inc.